ILMN · Illumina, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.09B | - | $1.08B | $1.06B | $1.04B | - | $1.08B | $1.11B | $1.08B | - |
| Cost of Revenue | $370.00M | - | $351.00M | $364.00M | $358.00M | - | $335.00M | $391.00M | $409.00M | - |
| Gross Profit | $721.00M | - | $733.00M | $695.00M | $683.00M | - | $745.00M | $721.00M | $667.00M | - |
| R&D | $240.00M | - | $229.00M | $247.00M | $252.00M | - | $253.00M | $325.00M | $339.00M | - |
| SG&A | $272.00M | - | $277.00M | $234.00M | $267.00M | - | $239.00M | $147.00M | $439.00M | - |
| Total Operating Expenses | $512.00M | - | $506.00M | $481.00M | $519.00M | - | $4.00M | $2.36B | $778.00M | - |
| D&A | $51.00M | - | $70.00M | $105.00M | $108.00M | - | - | - | $59.00M | - |
| Operating Income | $209.00M | - | $227.00M | $214.00M | $164.00M | - | $741.00M | ($1.64B) | ($111.00M) | - |
| Interest Expense | $24.00M | - | $25.00M | $25.00M | $25.00M | - | $36.00M | $20.00M | $18.00M | - |
| Income Tax | $23.00M | - | $70.00M | $71.00M | $51.00M | - | $15.00M | $12.00M | $17.00M | - |
| Net Income | $334.00M | - | $150.00M | $235.00M | $186.00M | - | $705.00M | ($1.99B) | ($126.00M) | - |
| EPS - Basic | $0.88 | - | $0.98 | $1.49 | $0.83 | - | $4.43 | ($12.48) | ($0.77) | - |
| EPS - Diluted | $0.87 | - | $0.98 | $1.49 | $0.82 | - | $4.42 | ($12.48) | ($0.77) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.09B | $1.42B | $1.05B | $934.00M | $1.11B | $1.13B | $869.00M | $920.00M | $1.11B | $1.05B |
| Accounts Receivable | $738.00M | $854.00M | $729.00M | $701.00M | $699.00M | $735.00M | $699.00M | $641.00M | $635.00M | $734.00M |
| Inventory | $611.00M | $564.00M | $590.00M | $575.00M | $537.00M | $547.00M | $574.00M | $561.00M | $584.00M | $587.00M |
| Accounts Payable | $218.00M | $240.00M | $218.00M | $200.00M | $207.00M | $221.00M | $191.00M | $199.00M | $201.00M | $245.00M |
| Current Assets | $2.74B | $3.29B | $2.80B | $2.64B | $2.67B | $2.75B | $2.37B | $2.46B | $2.58B | $2.61B |
| Total Assets | $6.56B | $6.64B | $6.18B | $6.09B | $6.18B | $6.30B | $6.01B | $6.08B | $10.04B | $10.11B |
| Current Liabilities | $1.57B | $1.58B | $1.96B | $1.46B | $1.44B | $1.55B | $975.00M | $2.21B | $1.47B | $1.57B |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | $2.68B | $2.72B | $2.38B | $2.26B | $2.37B | $2.37B | $2.13B | $1.44B | $5.73B | $5.75B |
| Retained Earnings | ($258.00M) | ($392.00M) | ($726.00M) | ($876.00M) | ($1.11B) | ($1.24B) | ($1.43B) | ($2.13B) | ($145.00M) | ($19.00M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $289.00M | - | - | - | $240.00M | - | - | - | $77.00M | - |
| Investing Cash Flow | ($366.00M) | - | - | - | ($63.00M) | - | - | - | ($48.00M) | - |
| Financing Cash Flow | ($251.00M) | - | - | - | ($195.00M) | - | - | - | $35.00M | - |
| CapEx | $38.00M | - | - | - | $32.00M | - | - | - | $36.00M | - |
| Free Cash Flow | $251.00M | - | - | - | $208.00M | - | - | - | $41.00M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 66.1% | - | 67.6% | 65.6% | 65.6% | - | 69.0% | 64.8% | 62.0% | - |
| Operating margin | 19.2% | - | 20.9% | 20.2% | 15.8% | - | 68.6% | -147.2% | -10.3% | - |
| EBITDA margin | 23.8% | - | 27.4% | 30.1% | 26.1% | - | - | - | -4.8% | - |
| Net margin | 30.6% | - | 13.8% | 22.2% | 17.9% | - | 65.3% | -178.8% | -11.7% | - |
| Free cash flow margin | 23.0% | - | - | - | 20.0% | - | - | - | 3.8% | - |
| FCF / Net income | 0.75 | - | - | - | 1.12 | - | - | - | -0.33 | - |
| R&D / Revenue | 22.0% | - | 21.1% | 23.3% | 24.2% | - | 23.4% | 29.2% | 31.5% | - |
| SG&A / Revenue | 24.9% | - | 25.6% | 22.1% | 25.6% | - | 22.1% | 13.2% | 40.8% | - |
| Effective tax rate | 6.4% | - | 31.8% | 23.2% | 21.5% | - | 2.1% | - | - | - |
| Return on assets | 5.1% | - | 2.4% | 3.9% | 3.0% | - | 11.7% | -32.7% | -1.3% | - |
| Return on equity | 12.5% | - | 6.3% | 10.4% | 7.9% | - | 33.2% | -138.4% | -2.2% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.75 | 2.08 | 1.43 | 1.81 | 1.86 | 1.78 | 2.43 | 1.11 | 1.75 | 1.66 |
| Quick ratio | 1.36 | 1.72 | 1.12 | 1.41 | 1.48 | 1.42 | 1.85 | 0.86 | 1.36 | 1.29 |
| Cash ratio | 0.70 | 0.89 | 0.54 | 0.64 | 0.77 | 0.73 | 0.89 | 0.42 | 0.75 | 0.67 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | 8.7x | - | 9.1x | 8.6x | 6.6x | - | 20.6x | -81.8x | -6.2x | - |
| Equity multiplier | 2.45 | 2.44 | 2.59 | 2.70 | 2.61 | 2.66 | 2.83 | 4.23 | 1.75 | 1.76 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | 0.17 | - | 0.18 | 0.17 | 0.17 | - | 0.18 | 0.18 | 0.11 | - |
| Inventory turnover | 0.61 | - | 0.59 | 0.63 | 0.67 | - | 0.58 | 0.70 | 0.70 | - |
| Days sales outstanding | 247d | - | 245d | 242d | 245d | - | 236d | 210d | 215d | - |
| Days inventory outstanding | 603d | - | 614d | 577d | 548d | - | 625d | 524d | 521d | - |
| Days payable outstanding | 215d | - | 227d | 201d | 211d | - | 208d | 186d | 179d | - |
| Cash conversion cycle | 635d | - | 632d | 618d | 582d | - | 654d | 548d | 557d | - |
| Valuation | ||||||||||
| P / E | 135.3x | - | 93.6x | 63.6x | 97.6x | - | 29.4x | - | - | - |
| P / B | 6.8x | - | 5.9x | 6.6x | 5.4x | - | 9.8x | 11.6x | 3.7x | - |
| P / S | 16.6x | - | 13.0x | 14.1x | 12.2x | - | 19.3x | 14.9x | 19.7x | - |
| EV / EBITDA | 65.5x | - | 44.0x | 43.7x | 42.7x | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 4.8% | - | 0.4% | -4.8% | -3.3% | - | -3.5% | -5.4% | -1.0% | - |
| Revenue CAGR (3y) | 0.1% | - | -0.9% | -3.0% | -5.2% | - | -0.8% | -0.4% | -0.5% | - |
| Revenue CAGR (5y) | -0.0% | - | 6.4% | 10.8% | 3.9% | - | 3.6% | 5.8% | 4.9% | - |
| Gross profit growth (YoY) | 5.6% | - | -1.6% | -3.6% | 2.4% | - | 8.9% | -1.5% | 1.8% | - |
| Operating income growth (YoY) | 27.4% | - | -69.4% | - | - | - | - | -1760.2% | -73.4% | - |
| Net income growth (YoY) | 79.6% | - | -78.7% | - | - | - | - | -749.6% | 9.4% | - |
| EPS growth (YoY) | 6.1% | - | -77.8% | - | - | - | - | -743.2% | - | - |
| EPS CAGR (3y) | 251.7% | - | - | - | 14.2% | - | 28.6% | - | - | - |
| EPS CAGR (5y) | -2.7% | - | -4.1% | 36.0% | -6.9% | - | 22.8% | - | - | - |
| FCF growth (YoY) | 20.7% | - | - | - | 407.3% | - | - | - | - | - |
| FCF CAGR (5y) | 0.9% | - | - | - | -2.9% | - | - | - | -22.0% | - |
| Book value growth (YoY) | 13.0% | 14.7% | 12.0% | 57.2% | -58.7% | -58.7% | -64.0% | -78.1% | -14.3% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-28.
Business segments
$8.69B totalCore Illumina$4.34B · 50.0%
Sequencing$3.98B · 45.9%
Microarray$358.00M · 4.1%
Product / service
$7.75B totalProduct$3.71B · 47.9%
Consumables$2.94B · 37.9%
Service$634.00M · 8.2%
Instruments$465.00M · 6.0%
Geographic
$6.59B totalAmericas$2.41B · 36.5%
US$2.24B · 34.1%
Europe$1.26B · 19.2%
Asia Pacific Middle East And Africa$430.00M · 6.5%
CN$243.00M · 3.7%
Peer comparison
Same SIC group: Laboratory Analytical Instruments
Comparing ILLUMINA against the 5 most active filers in the same SIC group.